Norbert Marschner

TL;DR: Among patients receiving initial systemic treatment for HR-positive, HER2-negative advanced breast cancer, the duration of progression-free survival was significantly longer among those receiving ribociclib plus letrozole than among those received placebo plus let rozole, with a higher rate of myelosuppression in the ribocIClib group.

TL;DR: 1 year of extended adjuvant therapy with neratinib, administered after chemotherapy and trastuzumab, significantly reduced the proportion of clinically relevant breast cancer relapses-ie, those that might lead to death, such as distant and locoregional relapses outside the preserved breast-without increasing the risk of long-term toxicity.

TL;DR: Dalteparin prophylaxis did not reduce the frequency of thromboembolic complications after CVC implantation in cancer patients and was demonstrated to be safe over 16 weeks of treatment in these patients.

TL;DR: Investigation of two doses of the fully human IgG1 anti-EpCAM antibody adecatumumab in patients with metastatic breast cancer shows dose- and target-dependent clinical activity in EpCAM-positive MBC, albeit no objective tumor regression.

TL;DR: The results suggest that continued VEGF inhibition with further bevacizumab is a valid treatment option for patients with locally recurrent or metastatic HER2-negative breast cancer whose disease was stabilised or responded to first-line bevacsumab with chemotherapy.